|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omloo JM, Lagarde SM, Hulscher JB, Reitsma
JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW and
van Lanschot JJ: Extended transthoracic resection compared with
limited transhiatal resection for adenocarcinoma of the mid/distal
esophagus: Five-year survival of a randomized clinical trial. Ann
Surg. 246:992–1001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andl CD, Mizushima T, Nakagawa H, Oyama K,
Harada H, Chruma K, Herlyn M and Rustgi AK: Epidermal growth factor
receptor mediates increased cell proliferation, migration, and
aggregation in esophageal keratinocytes in vitro and in vivo. J
Biol Chem. 278:1824–1830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rowinsky EK: Signal events: Cell signal
transduction and its inhibition in cancer. Oncologist. 8(Suppl 3):
5–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato-Kuwabara Y, Neves JI, Fregnani JH,
Sallum RA and Soares FA: Evaluation of gene amplification and
protein expression of HER2/neu in esophageal squamous cell
carcinoma using Fluorescence in situ Hybridization (FISH) and
immunohistochemistry. BMC Cancer. 9:62009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhan N, Dong WG, Tang YF, Wang ZS and
Xiong CL: Analysis of HER2 gene amplification and protein
expression in esophageal squamous cell carcinoma. Med Oncol.
29:933–940. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan DS, Twine CP and Lewis WG: Systematic
review and meta-analysis of the influence of HER2 expression and
amplification in operable oesophageal cancer. J Gastrointest Surg.
16:1821–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mimura K, Kono K, Hanawa M, Mitsui F,
Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER2/neu
expression and gene amplification in patients with oesophageal
squamous cell carcinoma. Br J Cancer. 92:1253–1260. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reichelt U, Duesedau P, Tsourlakis MCh,
Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A,
et al: Frequent homogeneous HER2 amplification in primary and
metastatic adenocarcinoma of the esophagus. Mod Pathol. 20:120–129.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schoppmann SF, Jesch B, Friedrich J, Wrba
F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M and
Birner P: Expression of HER2 in carcinomas of the esophagus. Am J
Surg Pathol. 34:1868–1873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friess H, Fukuda A, Tang WH, Eichenberger
A, Furlan N, Zimmermann A, Korc M and Büchler MW: Concomitant
analysis of the epidermal growth factor receptor family in
esophageal cancer: Overexpression of epidermal growth factor
receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg.
23:1010–1018. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki H, Abo S, Kitamura M, Hashimoto M,
Izumi K, Terada K and Sugiyama T: Gene amplification of int-2 and
erbB in human esophageal cancer: Relationship to
clinicopathological variables. Cancer Invest. 15:411–415. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura T, Nekarda H, Hoelscher AH,
Bollschweiler E, Harbeck N, Becker K, Siewert JR and Harbec N:
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein
overexpression in adenocarcinoma of Barrett's esophagus. Cancer.
73:1785–1794. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polkowski W, van Sandick JW, Offerhaus GJ,
ten Kate FJ, Mulder J, Obertop H and van Lanschot JJ: Prognostic
value of Laurén classification and c-erbB-2 oncogene overexpression
in adenocarcinoma of the esophagus and gastroesophageal junction.
Ann Surg Oncol. 6:290–297. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kato H, Arao T, Matsumoto K, Fujita Y, et
al: Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal
squamous cell carcinoma. Int J Oncol. 42:1151–1158. 2013.PubMed/NCBI
|
|
17
|
Thompson SK, Sullivan TR, Davies R and
Ruszkiewicz AR: HER2/neu gene amplification in esophageal
adenocarcinoma and its influence on survival. Ann Surg Oncol.
18:2010–2017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang LS, Chow KC, Chi KH, Liu CC, Li WY,
Chiu JH and Huang MH: Prognosis of esophageal squamous cell
carcinoma: Analysis of clinicopathological and biological factors.
Am J Gastroenterol. 94:1933–1940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hardwick RH, Barham CP, Ozua P, Newcomb
PV, Savage P, Powell R, Rahamin J and Alderson D:
Immunohistochemical detection of p53 and c-erbB-2 in oesophageal
carcinoma; no correlation with prognosis. Eur J Surg Oncol.
23:30–35. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leonard GD, Fojo T and Bates SE: The role
of ABC transporters in clinical practice. Oncologist. 8:411–424.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galimberti S, Marchetti A, Buttitta F,
Carnicelli V, Pellegrini S, Bevilacqua G and Petrini M: Multidrug
resistance related genes and p53 expression in human non small cell
lung cancer. Anticancer Res. 18:2973–2976. 1998.PubMed/NCBI
|
|
22
|
Yokoyama H, Ishida T, Sugio K, Inoue T and
Sugimachi K: Immunohistochemical evidence that P-glycoprotein in
non-small cell lung cancers is associated with shorter survival.
Surg Today. 29:1141–1147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tews DS, Nissen A, Külgen C and Gaumann
AK: Drug resistance-associated factors in primary and secondary
glioblastomas and their precursor tumors. J Neurooncol. 50:227–237.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Langer R, Specht K, Becker K, Ewald P,
Bekesch M, Sarbia M, Busch R, Feith M, Stein HJ, Siewert JR and
Höfler H: Association of pretherapeutic expression of
chemotherapy-related genes with response to neoadjuvant
chemotherapy in Barrett carcinoma. Clin Cancer Res. 11:7462–7469.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Title section/chapter. TNM Classification of Malignant Tumours
(7th). (Hoboken, NJ). Wiley-Blackwell. 4552009.
|
|
26
|
McShane LM, Altman DG, Sauerbrei W, Taube
SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC
Working Group on Cancer Diagnostics: REporting recommendations for
tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li
XX, Jiang LH, Wang Y, Zhu SM and Mao WM: Topo2A as a prognostic
biomarker for patients with resectable esophageal squamous cell
carcinomas. Med Oncol. 32:3962015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu XL, Zheng WH, Tao KY, Li XX, Xu WZ,
Wang Y, Zhu SM and Mao WM: p53 is an independent prognostic factor
in operable esophageal squamous cell carcinoma: A large-scale study
with a long follow-up. Med Oncol. 31:2572014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Konecny G, Pauletti G, Pegram M, Untch M,
Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M,
et al: Quantitative association between HER2/neu and steroid
hormone receptors in hormone receptor-positive primary breast
cancer. J Natl Cancer Inst. 95:142–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Owens MA, Horten BC and Da Silva MM: HER2
amplification ratios by fluorescence in situ hybridization and
correlation with immunohistochemistry in a cohort of 6,556 breast
cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parums DV: Current status of targeted
therapy in non-small cell lung cancer. Drugs Today (Barc).
50:503–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pollock NI and Grandis JR: HER2 as a
therapeutic target in head and neck squamous cell carcinoma. Clin
Cancer Res. 21:526–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kontopodis E, Kentepozidis N,
Christophyllakis CH, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas
L, Agelaki S, Kotsakis A, Vardakis N, et al: Docetaxel, gemcitabine
and bevacizumab as salvage chemotherapy for HER2-negative
metastatic breast cancer. Cancer Chemother Pharmacol. 75:153–160.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ,
Ryu HS, Kim YJ, Kim JH, Im SA, Gong G, et al: HER2 heterogeneity
affects trastuzumab responses and survival in patients with
HER2-positive metastatic breast cancer. Am J Clin Pathol.
142:755–766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Partridge AH, Rumble RB, Carey LA, Come
SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D,
et al: Chemotherapy and targeted therapy for women with human
epidermal growth factor receptor 2-negative (or unknown) advanced
breast cancer: American Society of Clinical Oncology Clinical
Practice Guideline. J Clin Oncol. 32:3307–3329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Raben D, Helfrich B, Chan DC, Ciardiello
F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr:
The effects of cetuximab alone and in combination with radiation
and/or chemotherapy in lung cancer. Clin Cancer Res. 11:795–805.
2005.PubMed/NCBI
|
|
37
|
Stoecklein NH, Hosch SB, Bezler M, Stern
F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel
WT, et al: Direct genetic analysis of single disseminated cancer
cells for prediction of outcome and therapy selection in esophageal
cancer. Cancer Cell. 13:441–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Birner P, Jesch B, Friedrich J, Riegler M,
Zacherl J, Hejna M, Wrba F, Schultheis A and Schoppmann SF:
Carbonic anhydrase IX overexpression is associated with diminished
prognosis in esophageal cancer and correlates with HER2 expression.
Ann Surg Oncol. 18:3330–3337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang G, Zhang W, Jiang W and Luan L:
Overexpression of HER2 associated with the progression of
esophageal cancer patients. Hepatogastroenterology. 60:1972–1978.
2013.PubMed/NCBI
|
